Q. Wu

发表

Phase I/II Trial of Combined Pegylated Liposomal Doxorubicin and Cyclophosphamide in Metastatic Breast Cancer

H. Linden, B. Kurland, J. Gralow, 2017, Clinical breast cancer.

Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal.

M. Sorror, N. Weiss, Stephanie J. Lee, 2019, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.

E. Krakow, R. Lynch, R. Cassaday, 2020, Clinical lymphoma, myeloma & leukemia.

γ-secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.

B. Wood, S. Riddell, A. Salter, 2019, Blood.

Hematopoietic cell transplantation after CD19 CAR T cell-induced ALL remission confers leukemia-free survival advantage.

W. Leisenring, M. Jensen, Julie R. Park, 2021, Transplantation and cellular therapy.

Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase BCMA Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

B. Wood, D. Maloney, C. Turtle, 2021, Blood.

Ultradeep, targeted sequencing reveals distinct mutations in blood compared to matched bone marrow among patients with multiple myeloma

E. Warren, D. Coffey, Yuexin Xu, 2019, Blood Cancer Journal.

Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma.

B. Gage, G. Lyman, N. Zakai, 2019, Journal of the National Comprehensive Cancer Network : JNCCN.

Inaccessible LCG Promoters Act as Safeguards to Restrict T Cell Development to Appropriate Notch Signaling Environments

R. Sandstrom, J. Stamatoyannopoulos, I. Bernstein, 2021, Stem cell reports.

The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML)

E. Estey, R. Walter, Seongseok Yun, 2018, Journal of drug assessment.

Management of venous thromboembolism during thrombocytopenia after autologous hematopoietic cell transplantation.

D. Garcia, A. Gopal, L. Holmberg, 2017, Blood advances.

Pembrolizumab with R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma: Long Term Follow up and Analysis of the Mechanism of Pdl-1 Tumor Expression

R. Lynch, M. Shadman, R. Cassaday, 2020 .

Prospective Study of Serial 18F-FDG PET and 18F-Fluoride PET to Predict Time to Skeletal-Related Events, Time to Progression, and Survival in Patients with Bone-Dominant Metastatic Breast Cancer

Paul Kinahan, D. Mankoff, H. Linden, 2018, The Journal of Nuclear Medicine.

Predictors of response to axicabtagene‐ciloleucel CAR T cells in aggressive B cell lymphomas: A real‐world study

D. Maloney, C. Turtle, R. Lynch, 2022, Journal of cellular and molecular medicine.

The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma

Ang Li, Greg Warnick, Gary H. Lyman, 2018, Annals of Hematology.

Peripheral lymphocytes and lactate dehydrogenase correlate with response and survival in head and neck cancers treated with immune checkpoint inhibitors

J. Liao, U. Parvathaneni, R. Martins, 2023, Cancer medicine.

Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat

G. Laramore, J. Liao, U. Parvathaneni, 2022, Head & neck.

Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients

N. Futran, G. Laramore, J. Liao, 2022, Cancer medicine.

The vascular bone marrow niche influences outcome in chronic myeloid leukemia via the E-selectin - SCL/TAL1 - CD44 axis

Martin C. Müller, K. Pan, D. Krause, 2019, Haematologica.

Urinary cross-linked carboxyterminal telopeptide, a bone resorption marker, decreases after vaso-occlusive crises in adults with sickle cell disease.

B. Konkle, E. Lipkin, R. Kruse-Jarres, 2020, Blood cells, molecules & diseases.

A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer.

H. Linden, B. Kurland, J. Gralow, 2021, Clinical breast cancer.

HIGH RATE OF DURABLE COMPLETE REMISSION IN FOLLICULAR LYMPHOMA AFTER CD19 CAR‐T CELL IMMUNOTHERAPY

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

Anakinra for refractory CRS or ICANS after CAR T-cell therapy.

D. Maloney, C. Turtle, E. Nemecek, 2023, Transplantation and cellular therapy.

GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients

Julie R. Park, Colleen Annesley, J. Gust, 2022, Blood advances.

Gender Differences in Faculty Rank and Subspecialty Choice among Academic Medical Oncologists

N. Davidson, Alexandra O. Sokolova, A. Khaki, 2020, Cancer investigation.

Outcomes Among Homeless Patients With Non–Small-Cell Lung Cancer: A County Hospital Experience

H. Linden, C. Baik, Isaac C. Jenkins, 2020, JCO oncology practice.

Clinical Experience of CAR T Cell Immunotherapy for Relapsed and Refractory Infant ALL Demonstrates Feasibility and Favorable Responses

M. Jensen, M. Pulsipher, Julie R. Park, 2019, Blood.

High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy.

D. Maloney, C. Turtle, S. Riddell, 2019, Blood.

SCRI-CAR19x22v2 T Cell Product Demonstrates Bispecific Activity in B-ALL

Amanda M Li, Josh Gustafson, M. Jensen, 2021, Blood.

Novel CD19t T-Antigen Presenting Cells Expand CD19 CAR T Cells In Vivo

M. Jensen, Julie R. Park, Colleen Annesley, 2019, Blood.

Lentivirus-carrying glypican-6 shRNA inhibits viability and colony formation of human nasopharyngeal carcinoma cells

Lei Liu, Shixi Liu, M. Nie, 2018 .

The incidence of thromboembolism for lenalidomide versus thalidomide in older patients with newly diagnosed multiple myeloma

G. Lyman, D. Garcia, E. Libby, 2019, Annals of Hematology.

Efficacy and Safety of Fully Human Bcma CAR T Cells in Combination with a Gamma Secretase Inhibitor to Increase Bcma Surface Expression in Patients with Relapsed or Refractory Multiple Myeloma

B. Wood, D. Maloney, C. Turtle, 2019, Blood.

External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment

D. Garcia, Ang Li, A. Li, 2018, Journal of thrombosis and haemostasis : JTH.

Modified manufacturing process modulates CD19CAR T-cell engraftment fitness and leukemia-free survival in pediatric and young adult subjects.

M. Jensen, M. Pulsipher, Julie R. Park, 2022, Cancer immunology research.